Havrix Adultes (Hepatitis A Virus (Inactivated), Aluminium Hydroxide)

Havrix Adultes is indicated for the prevention of hepatitis A virus infection in adults.

• Active immunization of individuals who have not been previously exposed to hepatitis A virus.
• Protection of travelers to regions where hepatitis A is endemic or where outbreaks occur.
• Immunization of people at increased risk due to occupational exposure, such as laboratory personnel handling hepatitis A specimens.
• Use in outbreak control situations to rapidly increase population immunity.

Side effects reported after Havrix Adultes administration are generally mild and transient.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue.

Serious

• Severe allergic reaction (anaphylaxis).
• Guillain‑Barré syndrome (rare).

Precautions for Havrix Adultes focus on patient history and potential adverse reactions.

• Do not administer to individuals with a known severe allergy to any vaccine component.
• Defer vaccination in persons experiencing an acute moderate or severe illness.
• Counsel patients that mild local reactions are common and usually resolve without treatment.
• Monitor for signs of anaphylaxis for at least 15 minutes after injection.
• Use with caution in pregnant or breastfeeding women; discuss risk‑benefit with a healthcare professional.

Havrix Adultes has limited documented drug interactions, but certain situations warrant attention.

Avoid

• Concomitant administration of other vaccines containing live attenuated viruses without appropriate interval.
• Use of immunosuppressive therapies that may diminish vaccine response.

Use with caution

• Antipyretics (e.g., acetaminophen) taken prophylactically may reduce antibody response; use only if needed for symptom relief.
• Concurrent administration of blood products or immunoglobulins may interfere with vaccine efficacy.
• Patients on chronic corticosteroid therapy should be evaluated for adequate immune response.